Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay

Supplemental Digital Content is Available in the Text.

[1]  S. Vermeire,et al.  Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study , 2022, Alimentary pharmacology & therapeutics.

[2]  J. Cheesbrough,et al.  Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab , 2022, Frontline Gastroenterology.

[3]  T. Wyant,et al.  Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials , 2020, The AAPS Journal.

[4]  S. Vermeire,et al.  S0652 Real World Exposure-Response Relationship of Vedolizumab in Inflammatory Bowel Disease: A Pooled Multicenter Observational Cohort Analysis of Clinical and Modeled Pharmacological Data , 2020 .

[5]  S. Connor,et al.  A Comparative Evaluation of Four Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies. , 2020, Therapeutic drug monitoring.

[6]  S. Vermeire,et al.  Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. , 2020, Gastroenterology.

[7]  G. Kaplan,et al.  Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  Yow-Ming C Wang,et al.  Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm? , 2018, The AAPS Journal.

[9]  E. Rey,et al.  Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels , 2018, Therapeutic advances in gastroenterology.

[10]  J. Stein,et al.  A prospective cohort study to assess the relevance of Vedolizumab drug level monitoring in IBD patients , 2017, Zeitschrift für Gastroenterologie.

[11]  V. Bosó,et al.  Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice , 2017, Inflammatory bowel diseases.

[12]  S. Connor,et al.  Comparison of infliximab drug measurement across three commercially available ELISA kits. , 2016, Pathology.

[13]  N. Vande Casteele.  Assays for measurement of TNF antagonists in practice , 2016, Frontline Gastroenterology.

[14]  M. Daperno,et al.  Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  G. Shankar,et al.  Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade® , 2016, The AAPS Journal.

[16]  D. Giavarina.  Understanding Bland Altman analysis , 2015, Biochemia medica.

[17]  W. Sandborn,et al.  Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[18]  K. Bendtzen,et al.  Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial , 2014, The American Journal of Gastroenterology.

[19]  L. Peyrin-Biroulet,et al.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[21]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[22]  S. Vermeire,et al.  Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays , 2012, Alimentary pharmacology & therapeutics.

[23]  D. Freeth,et al.  A methodological study to compare survey-based and observation-based evaluations of organisational and safety cultures and then compare both approaches with markers of the quality of care. , 2012, Health technology assessment.

[24]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[25]  J. Fleiss,et al.  The measurement of interrater agreement , 2004 .

[26]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[27]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[28]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .